2558 NEW ZEALAND GAZETTE, No. 96 30 AUGUST 2007

• of a person with an intellectual disability must
  participate in all aspects of the audit.

● For people with psychiatric disabilities or mental
illnesses, a past or present consumer of
mental health services must fully participate in
all aspects of the audit.

2. The auditing agency is required to conduct health and
   disability focused audits, together with a compliance
   audit against the requirements of the Health and
   Disability Services (Safety) Act 2001 annually.

3. The auditing agency is required to conduct health
   and disability services sector focused management
   reviews annually.

4. The auditing agency is required to provide written
   details of its internal appeals process to all clients.

This notice, which expires on 2 August 2008, revokes in
its entirety the notice that designated Telarc Limited
pursuant to section 32 of the Health and Disability
Services (Safety) Act 2001, published in the New Zealand
Gazette, 21 September 2006, No. 109, page 3242.”

Dated at Wellington this 22nd day of August 2007.

S. MCKERNAN, Director-General of Health.

go5947

Intellectual Disability (Compulsory Care and
Rehabilitation) Act 2003

Revocation of Appointment as Compulsory
Care Co-ordinator

Under section 140 of the Intellectual Disability (Compulsory
Care and Rehabilitation) Act 2003, I revoke the appointment
of the following person as a compulsory care co-ordinator
for the named geographical and operational area listed
below.

Central region including Manawatu-Wanganui, Palmerston
North, Hawke’s Bay, Wairarapa and Wellington:

Dian Birchall

The revocation of this appointment takes effect on the date
this notice is published in the New Zealand Gazette.

Dated at Wellington this 21st day of August 2007.

STEPHEN MCKERNAN, Director-General of Health.

go5970

Medicines Act 1981

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new medicine set out in the Schedule hereto:

Schedule

Product:
Aclasta

Active Ingredient:
Zoledronic acid 0.05mg/mL

Dosage Form:
Solution for infusion

New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector

Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Dated this 23rd day of August 2007.

ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by
the Minister of Health on 6 July 2001).

go5909

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the changed medicine which was referred to the Minister of Health, under the provisions of section 24(5) of the Act, and is set
out in the Schedule hereto:

Schedule

Product:
Infanrix-hexa (Combination Product)

Active Ingredients:
Diphtheria toxoid, adsorbed 30IU/dose
Hepatitis B surface antigen, recombinant 10µg/dose
Pertactin 8µg/dose
Pertussis filamentous haemagglutinin 25µg/dose
Pertussis toxoid, adsorbed 25µg/dose
Polio virus type 1 40DAgU
Polio virus type 2 8DAgU
Polio virus type 3 32DAgU
Tetanus toxoid, adsorbed 40IU/dose

Dosage Form:
Suspension for injection

Manufacturer:
GlaxoSmithKline Biologicals SA, Rixensart, Belgium

Active Ingredient:
Haemophilus influenzae type b vaccine 10µg/dose

Dosage Form:
Powder for injection

Manufacturer:
GlaxoSmithKline Biologicals SA, Rixensart, Belgium

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited